<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23959">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794857</url>
  </required_header>
  <id_info>
    <org_study_id>NP001-10-003</org_study_id>
    <nct_id>NCT02794857</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuraltus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuraltus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence
      of systemic inflammation. Half of participants will receive NP001 and the other half will
      receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study of NP001 in subjects with ALS
      and evidence of elevated systemic inflammation. Subjects will be allocated (1:1) to NP001
      and placebo. Drug or placebo will be given intravenously.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in score on ALS Functional Rating Scale-Revised (ALSFRS-R) questionnaire</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function as measured by slow vital capacity readings</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tracheotomy</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of blood inflammatory biomarkers</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>NP001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP001 2 mg/kg by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP001</intervention_name>
    <arm_group_label>NP001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of clinically possible, clinically probable (with or without laboratory
             support), or clinically definite ALS (using the revised El Escorial Criteria)

          -  Forced vital capacity greater than or equal to 65% of that predicted for age and
             height

          -  Onset of ALS-related weakness less than 3 years prior to first dose of study drug

          -  Plasma high sensitivity C-reactive protein (hs-CRP) concentration of greater than or
             equal to 0.113 mg/dL at pre-screening/screening

          -  Stable dose (greater than 30 days) of riluzole if undergoing treatment with this
             agent

          -  For females: Not be of childbearing potential or agree to use adequate birth control
             during the study

        Key Exclusion Criteria:

          -  Life expectancy of less than 6 months

          -  Tracheotomy or be using ventilatory assistance, including Bi-level Positive Airway
             Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP)

          -  Active pulmonary disease

          -  Gastrostomy

          -  Stem cell therapy

          -  Immune modulator therapy or participation in studies of other agents within 12 weeks
             of pre-screening/screening

          -  Unstable medical condition other than ALS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil Block, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Neuraltus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert G. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frances Faurot</last_name>
    <phone>415-912-1981</phone>
    <email>ffaurot@neuraltus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Reece</last_name>
      <phone>602-406-4775</phone>
      <email>Ashley.Reece@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Shafeeq Ladha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisa Powell</last_name>
      <phone>480-301-8788</phone>
      <email>powell.alisa@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vy Nguyen</last_name>
      <phone>424-315-2361</phone>
      <email>vy.nguyenx@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Richard Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine, Department of Neurology</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92862</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veena Mathew</last_name>
      <phone>714-456-2864</phone>
      <email>vmathew@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Namita Goyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Forbes Norris MDA/ALS Research Center, CPMC</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dallas A. Forshew, RN, BSN</last_name>
      <phone>415-309-5178</phone>
      <email>ForsheD@cpmcri.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan S. Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Palmucci, B.A.</last_name>
      <phone>904-953-3182</phone>
      <email>Palmucci.Carla@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bjorn E. Oskarsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Steele, RN</last_name>
      <phone>305-243-7336</phone>
      <email>jsteele@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Benatar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University, Department of Neurology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meraida Polak, RN</last_name>
      <phone>404-778-3807</phone>
      <email>mpolak@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Christina Fournier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Nichols</last_name>
      <phone>913-945-9945</phone>
      <email>Cnichols2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Richard J. Barohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Albert B. Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghann Bruno, RN, BSN</last_name>
      <phone>859-218-5064</phone>
      <email>Meghann.bruno@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Edward J. Kasarskis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Miller</last_name>
      <phone>617-724-7398</phone>
      <email>lmiller33@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Taylor Mezoian</last_name>
      <phone>617-643-0312</phone>
      <email>tmezoian@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>James Berry, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical &amp; Translational Science Institute, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Rolandelli, RN</last_name>
      <phone>612-624-7745</phone>
      <email>cnru@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Georgios Manousakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jess Singleton</last_name>
      <email>jes2186@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jinsy Andrews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center, Neurosciences Instutite-Neurology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Lary, RN</last_name>
      <phone>704-446-6063</phone>
      <email>Cynthia.lary@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Neurological Disorders Clinic at Morreene Road</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Grace, RN</last_name>
      <phone>919-668-2844</phone>
      <email>karen.grace@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Bedlack, MD, PhD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation-Cleveland Clinic Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irys B. Caristo</last_name>
      <phone>216-444-0173</phone>
      <email>Caristi@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Erik P. Pioro, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Heintzman</last_name>
      <phone>614-293-4973</phone>
      <email>sarah.heintzman@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Kolb, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Brain &amp; Spine Institute, ALS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlena Georgeson</last_name>
      <phone>503-962-1171</phone>
      <email>arlena.georgeson@providence.org</email>
    </contact>
    <investigator>
      <last_name>Kimberly Goslin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis F. Lay, Jr., CCRC</last_name>
      <phone>713-441-3057</phone>
      <email>LFLayjr@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Ericka Simpson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristiana Salmon</last_name>
      <phone>514-398-1779</phone>
      <email>kristiana.salmon@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Angela Genge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>May 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <keyword>Inflammation</keyword>
  <keyword>C-Reactive Protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
